Brooklyn ImmunoTherapeutics’ $125 Million Acquisition of Novellus

Philip Lee advised Novellus on the deal.

Brooklyn ImmunoTherapeutics has completed its acquisition of engineered cellular medicine company Novellus Therapeutics Limited.

This acquisition advances Brooklyn’s evolution into a platform company with a pipeline of next-generation engineered cellular, gene editing and cytokine programs.

Brooklyn ImmunoTherapeutics acquired Novellus for $125m which consisted of $23 million in cash and 7,022,230 shares of Brooklyn common stock, which were valued at a total of $102 million based on a price of approximately $14.53 per share.

Philip Lee M&A, led by Andy McConnell (Picture), was delighted to advise Novellus on this transaction.
 

Involved fees earner: Andreas McConnell – Philip Lee;

Law Firms: Philip Lee;

Clients: Novellus Therapeutics Limited;

Federica Tiefenthaler

Author: Federica Tiefenthaler

Brooklyn ImmunoTherapeutics’ $125 Million Acquisition of Novellus

Philip Lee advised Novellus on the deal.

Brooklyn ImmunoTherapeutics has completed its acquisition of engineered cellular medicine company Novellus Therapeutics Limited.

This acquisition advances Brooklyn’s evolution into a platform company with a pipeline of next-generation engineered cellular, gene editing and cytokine programs.

Brooklyn ImmunoTherapeutics acquired Novellus for $125m which consisted of $23 million in cash and 7,022,230 shares of Brooklyn common stock, which were valued at a total of $102 million based on a price of approximately $14.53 per share.

Philip Lee M&A, led by Andy McConnell (Picture), was delighted to advise Novellus on this transaction.
 

Involved fees earner: Andreas McConnell – Philip Lee;

Law Firms: Philip Lee;

Clients: Novellus Therapeutics Limited;

Federica Tiefenthaler

Author: Federica Tiefenthaler